Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (261-270 of 457) with videos related to

Pageof 46
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.
Transplantation and Cellular Therapy|August 18, 2024
Surrogates of Endothelial Injury Predict Survival After Post-transplant CyclophosphamideAnmol Baranwal, Kimberly J Langer, Mohamed A Kharfan-Dabaja, et al.
American Journal of Hematology|September 20, 2018
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational statusKebede H Begna, Walid Ali, Naseema Gangat, et al.
Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Blood Cancer Journal|June 17, 2020
A population-based study of chronic neutrophilic leukemia in the United StatesGordon J Ruan, Caleb J Smith, Courtney Day, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Transplantation|October 8, 2020
Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center ExperienceCarla Leal Moreira, M Hasib Sidiqi, Francis K Buadi, et al.
Blood Cancer Journal|February 20, 2024
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood Cancer Journal|October 7, 2025
Outcomes of older patients with TP53-mutated myeloid neoplasmsOmer Jamy, Mobachir El Kettani, Kashish Shah, et al.
Haematologica|March 28, 2024
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agentNickolas Steinauer, Kristen McCullough, Aref Al-Kali, et al.
Pageof 46

Showing results (261-270 of 457) with videos related to

Sort By:
Pageof 46
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.
Transplantation and Cellular Therapy|August 18, 2024
Surrogates of Endothelial Injury Predict Survival After Post-transplant CyclophosphamideAnmol Baranwal, Kimberly J Langer, Mohamed A Kharfan-Dabaja, et al.
American Journal of Hematology|September 20, 2018
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational statusKebede H Begna, Walid Ali, Naseema Gangat, et al.
Leukemia & Lymphoma|October 21, 2010
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status reportMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Blood Cancer Journal|June 17, 2020
A population-based study of chronic neutrophilic leukemia in the United StatesGordon J Ruan, Caleb J Smith, Courtney Day, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Transplantation|October 8, 2020
Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center ExperienceCarla Leal Moreira, M Hasib Sidiqi, Francis K Buadi, et al.
Blood Cancer Journal|February 20, 2024
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Talha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Blood Cancer Journal|October 7, 2025
Outcomes of older patients with TP53-mutated myeloid neoplasmsOmer Jamy, Mobachir El Kettani, Kashish Shah, et al.
Haematologica|March 28, 2024
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agentNickolas Steinauer, Kristen McCullough, Aref Al-Kali, et al.
Pageof 46